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ABSTRACT 
There are many components vitally essential to our biological function, and human-
ity tends to recognize, and often fight against, mounting threats to those very things. 
As a civilized society, Americans, in general, expect clean air, drinkable water, and 
safe food on a daily basis. However, a resource equally as essential to each of us is 
rarely recognized for its utility and necessity until a threat to its viability becomes 
personal. The blood shortage in the United States grows more critical every day, 
but for those of us lucky enough to not urgently need blood, the threat feels more 
removed and less important than similar threats to the air we breathe, the water we 
drink, and the food we consume. This article looks at the history of blood donation, 
collection, and supply in the United States, and how changing societal norms, un-
workable federal regulation, and misdirected economic influences are impacting the 
blood shortage crisis. The result is an urgent need to reconsider how the blood sup-
ply system could work to more efficiently solve for the even larger, more urgent 
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I. INTRODUCTION 
It may be a well-known television doctor who famously said, “it’s a beautiful 
day to save lives,”1 but realistically, doctors are not the only people who can save 
lives.2 In fact, before medical professionals can ever attempt to save a life, there is 
an inherent prerequisite that a sufficient blood supply exists for doctors to utilize in 
order to save the one out of seven patients needing a blood transfusion.3 Every day, 
hospitals throughout the country need approximately 41,000 units of blood, and the 
demand is endless.4 Therefore, in the United States, blood is a “critical national 
resource,”5 so a threat to this resource is a threat to human life. Regrettably, there is 
an increasingly dire threat to the blood supply that is being felt month after month 
and year after year—not only by blood donation centers and hospitals, but also by 
the people waiting for life-saving treatment.6 
Over the past decade, the United States has routinely found itself dealing with 
a constantly vulnerable blood supply.7 During 2008, blood collection and transfu-
sion peaked, with over 17 million units of red blood cells being collected.8 But by 
2015, blood collections had dropped 27.2% compared to 2008.9 The National Blood 
Collection and Utilization Survey concluded that the significant declines between 
2008 and 2015 resulted in an insufficient blood supply to meet routine demands 
nationwide.10 Although figures for collection rates are not yet available for 2016-
2018, projections expect the blood supply to continue to dwindle, weakening an 
already fragile system.11 Even without statistical data, concern over a persistent 
                                                          
        1. Top 10 Grey’s Anatomy Quotes, FAMOUS QUOTES & QUOTATIONS, http://www.famous-
quotes-and-quotations.com/greysanatomyquotes.html (last visited Mar. 25, 2019). 
        2. Jill Poet, Blood Donation: You Don’t Have to be a Doctor to Save Lives, HEALTHY LIFE ESSEX 
(Feb. 28, 2018), https://healthylifeessex.co.uk/2018/02/blood-donation-save-lives/ (citing the info-
graphic published by Study Medicine Europe). 
       3. ANDREW W. MULCAHY ET AL., RAND CORP., TOWARD A SUSTAINABLE BLOOD SUPPLY IN THE 
UNITED STATES: AN ANALYSIS OF THE CURRENT SYSTEM AND ALTERNATIVES FOR THE FUTURE iii 
(2016), https://www.rand.org/content/dam/rand/pubs/research_re-
ports/RR1500/RR1575/RAND_RR1575.pdf; Joseph A. Ibrahim, Why Blood Donations are so Im-
portant, ORLANDO HEALTH (Jan. 25, 2018), https://www.orlandohealth.com/blog/why-blood-dona-
tions-are-so-important; Blood Transfusions are Vital to Saving Lives, CARTER BLOODCARE (Aug. 1, 
2013), http://www.carterbloodcare.org/blood-transfusions-are-vital-to-saving-lives/. 
       4. Make a Difference Through Blood Donation, DRS. OSTEOPATHIC MED., https://doc-
torsthatdo.org/blood-donation-can-save-lives (last visited Mar. 25, 2019); Ibrahim, supra note 3. 
       5. Jay E. Menitove, The U.S. Blood System: Under Pressure, 15 HEMATOLOGIST 4, 4 (May 2018), 
https://www.hematology.org/Thehematologist/Past-Issues/8570.aspx. 
       6. Joe Severino, Red Cross Officials Call Blood Shortage ‘Dire’, CHARLESTON GAZETTE-MAIL 
(July 9, 2018), https://www.wvgazettemail.com/news/health/red-cross-officials-call-blood-shortage-
dire/article_aba5b311-9d54-5b40-b087-47a5ccf8983e.html. 
       7. Anne Lodge, Bioengineering Solutions to the Blood Supply Shortage, ASTARTE BIOLOGICS (Nov. 
30, 2017), https://astartebio.com/bioengineering-solutions-blood-supply-shortage/; see also Menitove, 
supra note 5, at 4. 
       8. Menitove, supra note 5, at 4 (“Red cell collections and transfusions peaked in 2008 at approxi-
mately 17,286,000 units collected, 17,159,000 units distributed, and 15,014,000 units transfused.”). 
       9. Id. (showing roughly 12.5 million red blood cells units were collected in 2015). 
       10. Katherine D. Ellingson et al., Continued Decline in Blood Collection and Transfusion in the 
United States–2015, 57 TRANSFUSION 1588, 1589 (June 2017), https://onlineli-
brary.wiley.com/doi/epdf/10.1111/trf.14165. 
       11. Menitove, supra note 5, at 4. 
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shortage is evidenced by the pleas of national and regional collection organizations 
and hospitals that are desperate for more donors.12 
With the country nearing a decade of continued blood shortage, there are mul-
tiple reasons why the United States cannot stay ahead of the need for blood. One 
factor, which is the most prominently and generally known, is how the lack of do-
nations from eligible donors has dramatically worsened.13 Whether the source of 
this decline is from the older generation of reliable donors beginning to age out14 or 
past blood donors lapsing and reducing their donation frequency,15 the blood indus-
try’s response needs to be revisited.16 Three additional factors that contribute to the 
blood shortage crisis stem from how the Food and Drug Administration (“FDA”) 
regulates the blood supply. First, donor deferrals, although necessary for a safe 
blood supply in general, have been temporarily or permanently assigned—often er-
roneously, and usually avoidably—to a growing proportion of otherwise willing 
donors.17 
Second, the FDA currently accepts no substitutions for human blood despite 
the availability of alternative synthetic products that are not only universally com-
patible and more readily available but also increasingly safe.18 This regulation con-
sequently results in a less flexible blood supply system, putting more pressure on 
collection organizations to recruit new or recruit lapsed donors—a lone strategy that 
has been empirically ineffective at curbing the blood shortage.19 A final component 
of the decade-long shortage stems from another regulatory shortcoming; the FDA 
                                                          
       12. Significant Shortages Impact U.S. Blood Supply, AM. RED CROSS (July 11, 2016), 
https://www.redcross.org/about-us/news-and-events/press-release/Significant-Shortages-Impact-US-
Blood-Supply.html [hereinafter Significant Shortages Impact]; Emergency Blood Shortage: Red Cross 
Issues Urgent Call for Blood Donors, AM. RED CROSS (July 9, 2018), https://www.redcrossblood.org/lo-
cal-homepage/news/article/emergency-blood-shortage--red-cross-issues-urgent-call-for-blood.html. 
       13. Ryan Patterson, National Drop in Blood Donors Hits Sheridan, CASPER STAR TRIB. (Aug. 3, 
2018), https://trib.com/news/state-and-regional/national-drop-in-blood-donors-hits-sheridan/arti-
cle_2c6608b8-4208-5faa-921c-543cb6cf40c1.html. 
       14. JoNel Aleccia, As Loyal Blood Donors Age, Industry is out for Young Blood, USA TODAY (Sept. 
24, 2017, 12:01 AM), https://www.usatoday.com/story/news/health/2017/09/24/loyal-blood-donors-
age-industry-out-young-blood/683714001/. 
       15. Johanne Charbonneau et al., Why Do Blood Donors Lapse or Reduce Their Donation’s Fre-
quency?, 30 TRANSFUSION MED. REVS. 1, 1 (Jan. 2016), https://ac.els-cdn.com/S0887796315001169/1-
s2.0-S0887796315001169-main.pdf?_tid=979cd3a3-c81e-4b14-bb97-e4341f798d89&ac-
dnat=1538241592_636c4aca3fb009f7bf044c11554ce070. 
       16. C.K. Lee, Update on Donor Recruitment Management in Blood Service, 11 INT’L SOC’Y BLOOD 
TRANSFUSION 69 (June 28, 2016), https://onlinelibrary.wiley.com/doi/full/10.1111/voxs.12265. 
       17. See generally Suhailur Rehman et al., The Evaluation of Blood Donor Deferral Causes, 3 J. 
BLOOD DISORDERS & TRANSFUSION 1 (Oct. 2012), https://www.omicsonline.org/the-evaluation-of-
blood-donor-deferral-causes-a-tertiary-care-centrebasedstudy-2155-9864.1000131.pdf (showing data 
explaining possible reasons why donors may be deferred by collection centers); Brian Custer et al., 
Quantifying Losses to the Donated Blood Supply due to Donor Deferral and Miscollection, 44 J. AABB: 
TRANSFUSION 1417 (Sept. 22, 2004), https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1537-
2995.2004.04160.x; Kusum D. Jashnani & Laxmi N. Patil, Blood Donor Deferrals: Can This be Re-
duced?, 5 ASIAN J. TRANSFUSION SCI. 60 (Jan. 2011), https://www.ncbi.nlm.nih.gov/pmc/arti-
cles/PMC3082725/; P. A. Tomasulo et al., A Study of Criteria for Blood Donor Deferral, 20 J. AABB: 
TRANSFUSION 511 (Sept. 1980), https://onlinelibrary.wiley.com/doi/abs/10.1046/j.1537-
2995.1980.20581034503.x?sid=nlm%3Apubmed. 
       18. Nina Notman, Red Blood Cell Substitutes, CHEMISTRY WORLD (Feb. 16, 2018), 
https://www.chemistryworld.com/feature/artificial-blood/3008586.article. 
       19. Custer et al., supra note 17. 
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does nothing to combat widespread “misuse of the blood supply” by hospitals, in-
cluding doctors’ tendencies to overprescribe blood transfusions.20 
Regardless of the exact combination of factors causing the blood shortage, the 
enormous impacts of the ongoing crisis are at the great expense of patients and their 
families. Usually, the human cost and the economic cost go hand-in-hand, where 
[a]n inadequate blood supply may pose a danger to patients if the proper 
amount and type of blood is not available when needed. It may lead to 
longer hospital stays if elective procedures must be postponed in order to 
wait for an adequate blood supply. This leads to increased costs, as well as 
potential risks for patients.21 
In much more severe circumstances, “blood shortages become so critical that 
major surgeries and other hospital procedures that require blood transfusions will 
halt entirely. For patients who need urgent surgery, this can mean the difference 
between life and death.”22 Here, the potential human cost does not need to be sup-
plemented with an associated economic cost for the impact to be disastrously unac-
ceptable. 
In addition to the impact on patients, the negative impacts of consistent blood 
shortages are also felt by the healthcare industry. The U.S. Department of Health 
and Human Services contracted the RAND Corporation to assess instability within 
the blood supply system, aiming to understand the economic implications of the 
crisis on the industry.23 The shortage from 2008 to 2015, in conjunction with other 
trends,24 resulted in over 90% of blood providers’ expenses exceeding revenues in 
2016.25 Obstacles created by the shortage result in cost increases for hospitals, 
which relatedly increases the financial pressure on blood centers when they absorb 
the associated costs.26 Simply put, when there is less blood collected, there is less 
blood to sell; when there is less blood to sell, blood centers lose revenue and hospi-
tals incur greater costs to buy whatever blood is available. However, the Advisory 
Committee on Blood and Tissue Safety distinguishes that normal “supply and de-
mand economic principles do not fully address the societal value of” blood as a 
“critical national resource.”27 This important distinction surely adds further com-
plexity and uniqueness to the problem at hand, but neither the complex nor unique 
                                                          
       20. Colin Hemez, Blood Transfusion Costs, YALE GLOBAL HEALTH REV. (Dec. 21, 2016), 
https://yaleglobalhealthreview.com/2016/12/21/blood-transfusion-costs/. 
       21. Jeffrey McCullough, Blood Supply Fluctuations, in BLOOD DONORS AND THE SUPPLY OF BLOOD 
AND BLOOD PRODUCTS 9, 9 (Frederick J. Manning & Linette Sparacino eds., 1996), 
https://www.ncbi.nlm.nih.gov/books/NBK233132/pdf/Bookshelf_NBK233132.pdf. 
       22. The Impact of Blood Shortages on American Healthcare, RATE HOSPS. (Jan. 21, 2014), 
https://web.archive.org/web/20170731190327/http://www.ratehospitals.com/blog/the-impact-of-blood-
shortages-on-american-healthcare/. 
       23. Menitove, supra note 5, at 4 (The RAND Corporation is a global nonprofit think tank, funded 
privately and by the U.S. government to research and develop solutions to public policy challenges, 
including the blood shortage.). 
       24. Id. (detailing how additional factors are influencing the industry, such as a declining number of 
transfusions). 
       25. Id. 
       26. Id. 
       27. Id. 
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nature of the problem excuses the urgent obligation of relevant officials and agen-
cies to find and implement a near-term solution.28 
Despite the obviously troublesome situation, the FDA boldly noted in early 
2018 how “the blood supply is safer than it ever has been.”29 While that may be 
true for the supply of blood which is physically collected and transfused, the sus-
tainability of the blood supply faces great risks. One may argue, as this article does, 
that because the blood supply system lacks sufficient resiliency, the blood supply is 
thereby less safe than it ever has been.30 Leaders of transfusion medicine—those 
who navigate and deal with the blood supply shortage on a daily basis—agreed with 
this point in 2017 when they 
conclude[d] that ‘allowing the U.S. blood system to function as it has while 
it is losing stability, resilience, and surge capacity is not a responsible op-
tion,’ and caution[ed] that ‘a constructive intervention to stabilize the U.S. 
blood system, although urgently needed, has yet to be envisioned.’ The 
importance of addressing these issues . . . is obligatory. . . .31 
After analyzing the social and legal history of the industry in Part II, this article 
further reveals the unfortunate status quo of the blood supply industry in Part III. 
Then, Part IV suggests various reconsiderations of the current system in order to 
revitalize and stabilize the blood supply, drawing upon a creative combination of 
social, political, legal, economic, and scientific perspectives. 
First, subsection A of Part IV discusses how blood collection organizations 
must make greater, more focused use of social media marketing. Strategically uti-
lizing modern advertising tools will allow easier dissemination of relevant infor-
mation to the public. Because social media is a relatively easy approach to revamp-
ing an organization’s marketing, and the public is the inherent pool of potential 
donors, this change is both practical and necessary. 
Second, subsections B and C of Part IV discuss how the remainder of necessary 
changes lies in altering current FDA regulations and guidance. Among these 
changes are: (1) popularizing blood donor incentivization through tax credits or di-
rect payments to draw in new donors and retain current/past donors; (2) clarifying 
both the standards and process for donor requalification, following either temporary 
or indefinite donor deferrals; and (3) allowing the regular use of synthetic blood 
alternatives beyond the limited, exceptional uses allowed currently. 
Finally, the conclusion in Part V synthesizes how urgently a solution is needed, 
whether it involves the solutions discussed in Part IV or involves an entirely differ-
ent idea yet to be discovered and developed. Regardless, a “robust, sustainable 
blood system is a crucial component of every health care system.”32 In order for 
medical professionals to ensure the safety of current and future patients’ lives, the 
nation must first ensure the safety of our at-risk blood supply. 
                                                          
       28. Id. 
       29. Blood & Blood Products, FDA, https://www.fda.gov/biologicsbloodvaccines/bloodbloodprod-
ucts/default.htm (last updated Feb. 2, 2018) (emphasis added). 
       30. Menitove, supra note 5, at 4 (citing to the U.S. Department of Health and Human Services, 
Advisory Committee on Blood and Tissue Safety and Availability (Nov. 2016)). 
       31. Id. 
       32. MULCAHY ET AL., supra note 3. 
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II.  OVERVIEW OF RELEVANT BLOOD COLLECTION AND SUPPLY LAW 
IN THE UNITED STATES 
Blood banking in the United States first began in 1936 and has since developed 
into a sophisticated blood supply system.33 Essential to the development of the sys-
tem was a 1972 report from the U.S. Department of Health, Education, and Welfare, 
stating 
several problems within the blood supply system, including an inadequacy 
in the quantity of blood supplied, an unreliability in the quality of blood 
owing to the high rates of transfusion-related hepatitis, an inefficiency in 
the system itself owing to waste in some areas and shortages in others, and 
excessive costs of blood and blood services.34 
The corresponding result was the creation of the National Blood Policy in 1973, 
which nationally standardized all blood donation and collection practices and be-
came “the focal point around which blood banking policy has evolved” over time.35 
It was this policy that first encouraged efforts to end paid blood donations and, in-
stead, establish a purely volunteer blood donation system that hoped to eliminate 
commercialism in the acquisition of transfusable blood.36 
Presently, the U.S. blood system has grown into a complex function of multiple 
moving parts: “donors; blood centers; suppliers of equipment, goods, and services 
used in the blood system; hospitals and clinics; and patients.”37 In addition, the FDA 
is a key component of the blood supply process because it authorizes the regulation 
of all biologic products, “including blood and blood-components.”38 The  process 
of supplying blood in the United States begins with the blood collected from donors 
at blood collection organizations, hospitals, or the like, all of which are registered 
and licensed by the FDA.39 Using the 2016 data collected under the research con-
tract with the Department of Health and Human Services, The RAND Corporation 
determined there were 786 registered blood collection organizations on top of an-
other 725 hospital and nonhospital blood banks.40 
A few large, national organizations comprise and operate the majority of blood 
collection organizations: AABB, The American Red Cross, and America’s Blood 
Centers.41 Formerly titled the American Association of Blood Banks, AABB is an 
                                                          
       33. Blood Banking and Donation, AM. SOC’Y HEMATOLOGY, https://www.hematology.org/Pa-
tients/Basics/Banking.aspx (last visited Mar. 25, 2019). 
       34. INST. OF MED. (U.S.) COMM. TO STUDY HIV TRANSMISSION THROUGH BLOOD AND BLOOD 
PRODUCTS, HIV AND THE BLOOD SUPPLY: AN ANALYSIS OF CRISIS DECISIONMAKING 41 (Lauren B. 
Leveton et al. eds., 1995), https://www.ncbi.nlm.nih.gov/books/NBK232409/#_ddd00056_ [hereinafter 
HIV AND THE BLOOD SUPPLY]. 
       35. Id. (citing OTA 1985); see also History of Blood Transfusion, AM. RED CROSS, https://www.red-
crossblood.org/donate-blood/blood-donation-process/what-happens-to-donated-blood/blood-transfu-
sions/history-blood-transfusion.html (last visited Mar. 25, 2019). 
       36. HIV AND THE BLOOD SUPPLY, supra note 34, at 41 (citing the Federal Register 1975). 
       37. MULCAHY ET AL., supra note 3, at 7. 
       38. Id. at 10. 
       39. Id. at 11. 
       40. Id. at 12; see also Menitove, supra note 5, at 4. 
       41. Significant Shortages Impact, supra note 12. 
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international, not-for-profit association that represents individuals and accredits in-
stitutions involved in blood donation and transfusion medicine.42 The American 
Red Cross is also a not-for-profit organization, and alone it supplies “about 40% of 
our nation’s blood and blood components” among its other numerous humanitarian 
aid missions.43 America’s Blood Centers was founded in 1962 and is the largest 
network of independent and community blood programs in North America.44 As 
indicated by The RAND Corporation’s research, some hospitals also have their own 
blood collection centers but supplement their supplies with blood from national or 
regional organizations.45 
As a whole, the blood industry is a $4.5 billion-a-year business, accounting for 
the operating expenses of collecting blood and the revenue gained from its sale.46 
Although the costs of collecting and supplying blood for transfusions vary around 
the country,47 the blood shortage and its associated financial burdens on the blood 
industry are causing concern nationwide.48 Of primary concern is that the cost of 
blood continues to increase,49 prompting industry experts to suggest that this 
knowledge of rising prices “should be used by organizations and policy makers to 
improve financing and utilization management.”50 A preliminary understanding of 
the current policies governing the management and regulation of the blood supply 
system, as well as the agencies and organizations authorized to control it, is an es-
sential foundation that must be laid out before undertaking any construction of po-
tential solutions to the blood shortage crisis. 
A. Statutory Influence on the Blood Supply 
The main statutory sources regulating blood collection and supply in the United 
States, as well as authorizing the agencies and regulations discussed below,51 are 
the Public Health Service Act (“PHSA”),52 and the Federal Food, Drug, and Cos-
metic Act (“FDCA”).53 
Concerned primarily with giving “a policy framework for federal [and] state 
cooperation in [advancing] public health,” the PHSA includes provisions about 
                                                          
       42. Id. 
       43. Blood Needs & Blood Supply, AM. RED CROSS, https://www.redcrossblood.org/donate-
blood/how-to-donate/how-blood-donations-help/blood-needs-blood-supply.html (last visited Mar. 25, 
2019). 
       44. Significant Shortages Impact, supra note 12.        45. MULCAHY ET AL., supra note 3, at 9; Menitove, supra note 5. 
       46. Erin Carlyle, The Guys Who Trade Your Blood for Profit, FORBES (June 27, 2012, 1:13 PM), 
https://www.forbes.com/sites/erincarlyle/2012/06/27/blood-money-the-guys-who-trade-your-blood-
for-profit/#4bfa6c24282e; see also Kathleen M. Berry, All About/Blood Banks; A Multibillion-Dollar 
Business in a Nonprofit World, N.Y. TIMES (July 7, 1991), https://www.nytimes.com/1991/07/07/busi-
ness/all-about-blood-banks-a-multibillion-dollar-business-in-a-nonprofit-world.html. 
       47. Hemez, supra note 20. 
       48. MULCAHY ET AL., supra note 3, at xiii. 
       49. Richard W. Toner et al., Costs to Hospitals of Acquiring and Providing Blood in the US, 9 
APPLIED HEALTH ECON. & HEALTH POL’Y 29 (2011), https://link.springer.com/arti-
cle/10.2165/11530740-000000000-00000. 
       50. Id. 
       51. See infra Part II.A. 
       52. Public Health Service Act, 42 U.S.C. §§ 201-300 (2018). 
       53. Federal Food, Drug, and Cosmetic Act, 21 U.S.C. §§ 301-399 (2018). 
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blood donation and transfusion.54 Consistent with its policy aim, the PHSA estab-
lished “a program of research and education regarding blood donations and trans-
fusions to maintain and improve the safety of the blood supply.”55 An additional 
relevant section allows authorized persons to have access to a Blood Donor Locator 
Service, which provides such persons with the mailing address of previously eligi-
ble donors determined to be infected with, or at risk of, blood related infections.56 
The FDCA authorizes the FDA to oversee the safety of foods, drugs, and cosmet-
ics,57 including the duty to oversee the safety of the U.S. blood supply.58 
B. Regulation of the Blood Supply 
The growing complexity of the modern blood supply system since its institu-
tion in 1973 is apparent in the regulatory authority which authorizes and governs it. 
Conveniently, the Code of Federal Regulations sections relevant to blood collection 
and supply can be categorized fairly neatly into two broad areas: (1) the general 
nature and types of a blood donation, which trigger specific, individualized lan-
guage necessary for any analysis; and (2) the role of the blood donor in the blood 
supply system, encompassing the necessary determination of eligibility to donate. 
Before discussing these two areas, this subsection begins with a brief discussion of 
the agencies authorized to act in relation to the blood supply. 
The Center for Biologics Evaluation and Research (“CBER”) and its parent 
agency, the FDA, are responsible for regulating and overseeing the blood supply in 
the United States.59 Both the CBER and the FDA, in conjunction with the Public 
Health Service (“PHS”), are also responsible for identifying and responding to 
threats against blood safety or supply.60 The authority outlining the nature and scope 
of these responsibilities is found in federal statutes discussed above in subsection A 
and in the federal regulations discussed in the remainder of this subsection.61 
Viewed comprehensively, the CBER and the FDA work with other PHS organiza-
                                                          
       54. Public Health Service Act Law and Legal Definition, US LEGAL, https://definitions.usle-
gal.com/p/public-health-service-act/ (last visited Mar. 25, 2019); see also HIV AND THE BLOOD SUPPLY, 
supra note 34, at 48. 
       55. 42 U.S.C. § 300cc-19 (1988). 
       56. Id. § 1320b-11 (1994) (enabling relevant blood collection organization personnel to follow the 
FDA regulations requiring the notification of donors who test reactively for transfusion-transmitted in-
fections). 
       57. Federal Food, Drug, and Cosmetic Act of 1989 Law and Legal Definition, US LEGAL, 
https://definitions.uslegal.com/f/federal-food-drug-and-cosmetic-act-of-1938/ (last visited Mar. 25, 
2019). 
       58. Food and Drug Administration, WEST’S ENCYCLOPEDIA AM. L. (2005), https://www.encyclo-
pedia.com/social-sciences-and-law/political-science-and-government/us-government/food-and-drug-
administration; see also Theodore W. Ruger, Federal Food, Drug, and Cosmetic Act (1938), 
ENCYCLOPEDIA.COM (2004), https://www.encyclopedia.com/social-sciences-and-law/economics-busi-
ness-and-labor/businesses-and-occupations/drug-and-cosmetic (stating the FDA’s general authority to 
govern the safety of “blood and tissue products”). 
       59. Regulation of the Blood Supply, FDA, https://www.fda.gov/BiologicsBloodVaccines/Blood-
BloodProducts/RegulationoftheBloodSupply/default.htm (last updated Sept. 18, 2018) [hereinafter Reg-
ulation of the Blood Supply] (the FDA, as part of its responsibilities, “promulgates and enforces standards 
for blood collection and for the manufacturing of blood products.”). 
       60. Id. 
       61. Public Health Service Act, 42 U.S.C. § 201 (1993); Federal Food, Drug, and Cosmetic Act, 21 
U.S.C. § 301 (1938); Regulation of the Blood Supply, supra note 59. 
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tions, governmental agencies, “volunteer health organizations, universities, . . . sci-
entists, nongovernmental laboratories, and” biological product manufacturers to 
control the blood supply system in the United States.62 Even with so many entities 
sharing the responsibility, regulating the blood supply is no simple task. The pro-
ceeding discussion breaks down the two most fundamental areas of blood collection 
and supply regulation. 
First, blood donation and collection regulations are located in Title 21 of the 
Code of Federal Regulations under the Biologics Subchapter, most recently 
amended in 2015.63 Briefly, blood is defined as “a product that is a fluid containing 
dissolved and suspended elements which was collected from the vascular system of 
a human.”64 A blood component is “a product containing part of blood separated by 
physical or mechanical means.”65 These definitions imply the FDA does not author-
ize the use of synthetic blood alternatives because they are not collected from a 
human.66 
The humans who allow their blood to be collected are each identified as a 
“blood donor.”67 Consistent with its colloquial use, the FDA’s use of the word “vol-
unteer donor” denotes an individual “who does not receive monetary payment for a 
blood donation.”68 Since 1974, “the near-universal practice in the U.S.A. has been 
to collect blood and blood components for transfusion from volunteer donors who 
are not paid, consistent with the long-standing national policy” adopted around that 
time.69 Although there is no outright prohibition against instances of paid donation, 
the FDA requires whole blood and red blood cell donations that are “intended for 
transfusion” to be prominently labeled as either “paid donor” or “volunteer do-
nor.”70 Unfortunately, Johns Hopkins economist, Mario Macis, explains that while 
blood donations labeled “paid donor” are normally as usable and safe as donations 
labeled “volunteer donor,” hospitals still rarely use “paid donor” blood because of 
a generally unsupported, archaic determination that doing so would be unethical.71 
Whole blood donations, primarily composed of red blood cells, will eventually 
be transfused directly into the human patient—again, this type of donation must be 
labeled as “paid” or “volunteer.”72 Aside from red blood cells, whole blood also 
include platelets and plasma, all which can be separated out for unique purposes, 
but must still be labeled as “paid” or “volunteer.”73 Conversely, the FDA allows 
                                                          
       62. HIV AND THE BLOOD SUPPLY, supra note 34, at 45. 
       63. Requirements for Blood and Blood Components Intended for Transfusion or for Further Manu-
facturing Use, 80 Fed. Reg. 29841 (May 22, 2015). 
       64. 21 C.F.R. § 630.3(a) (2016). 
       65. Id. § 630.3(b); see About Blood: Blood Facts, COMMUNITY BLOOD CTR., http://giv-
ingblood.org/about-blood/blood-facts.aspx (last visited Mar. 25, 2019) (“One unit of blood can be sepa-
rated into several components: red blood cells, plasma, platelets, and cryoprecipitate.”). 
       66. 21 C.F.R. § 630.3(a)-(b). 
       67. Id. § 630.3(c). 
       68. Id. § 606.121(c)(8)(v)(B)-(C) (2016) (stating that benefits which “are not readily convertible to 
cash” are not “monetary payments”). 
       69. Paid vs. Unpaid Donors, 90 VOX SANGUINIS 63, 69–70 (2006), https://onlineli-
brary.wiley.com/doi/pdf/10.1111/j.1423-0410.2005.00708.x (referring to the National Blood Policy). 
       70. 21 C.F.R. § 606.121(c)(8)(v). 
       71. Elizabeth Preston, Why You Get Paid to Donate Plasma but not Blood, STAT (Jan. 22, 2016), 
https://www.statnews.com/2016/01/22/paid-plasma-not-blood/. 
       72. Id.; 21 C.F.R. § 606.121(c)(8)(v). 
       73. Whole Blood Donation, AM. RED CROSS, https://www.redcrossblood.org/donate-blood/how-to-
donate/types-of-blood-donations/whole-blood-donation.html (last visited Mar. 5, 2019); 21 C.F.R. § 
606.121(c)(8)(v). 
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targeted plasma donations to be compensated without any such labeling because 
plasma collections are never directly transfused into another person;74 rather, 
plasma is broken down in different parts and protein products, and it is then sold for 
pharmaceutical use.75 
In general, the controls for labeling, as well as for storage and testing, are indi-
vidualized for the type of donation being collected (e.g., red blood cells, plasma, 
platelets) and the way the donation was collected (i.e., voluntarily or paid).76 There-
fore, regulations also control the storage and testing of donated blood products be-
fore they can be sold for use because there are varying types of donations.77 Know-
ing the nature of the donation is only one piece of the regulatory puzzle, though. 
Next, examining the role of the human donor in the blood supply system, including 
the donor’s eligibility or ineligibly to donate, completes the puzzle. 
The second major area begins with the term “blood donor,” which includes 
both a person who successfully gives blood as well as “a person who . . . [p]resents 
as a potential candidate for such donation.”78 This naturally leads to the question: 
what makes an individual eligible to donate blood? The basic standard is that a do-
nor must be in good health and not present any factors that may negatively affect 
the “safety, purity, or potency of the blood or blood component.”79 To test a donor’s 
ability to meet this standard, blood collection organizations determine eligibility 
based on (1) the donor’s medical history, and (2) the donor’s performance during 
the physical assessment made immediately prior to the expected donation.80 There-
fore, a satisfactory medical history and physical assessment on the day of a planned 
donation means the donor is eligible to donate; an unsatisfactory medical history or 
physical assessment means the donor is ineligible to donate. Limiting eligibility for 
blood donation is an extremely effective way to ensure a safe blood supply, but it is 
also one of the more contentious issues surrounding blood donation regulation.81 
When circumstances deem a donor ineligible to donate blood, 21 C.F.R. § 
630.10(h) instructs blood collection organizations to defer the potential donor and 
“notify the donor of the deferral.”82 There are two types of deferral: (1) pre-dona-
tion, up-front deferrals determined by screening out donors prior to donating based 
on the physical assessment, and (2) post-donation deferrals based on testing the do-
nated blood sample for certain infections.83 Depending on which type of deferral is 
issued and its causal basis, people who had volunteered to donate blood will be 
prohibited from doing so either temporarily or permanently.84 Temporary deferrals 
                                                          
       74. Preston, supra note 71; see 21 C.F.R. 606.121(e)(5). 
       75. Preston, supra note 71. 
       76. How can One Donation Help Multiple People?, AM. RED CROSS, https://www.red-
crossblood.org/donate-blood/how-to-donate/types-of-blood-donations/blood-components.html (last vis-
ited Mar. 5, 2019). 
       77. 21 C.F.R. § 606.121; see also 21 C.F.R. § 610.40 (2016) (outlining the initial testing require-
ments that must be conducted on all donations of human blood or blood components). 
       78. 21 C.F.R. § 630.3(c) (2016). 
       79. Id. § 630.10(a)(2) (2016). 
       80. Id. § 630.10(d)-(f) (describing the specific medical history and physical health findings that must 
be obtained in order to donate blood); see id. § 630.10(g) (stating the “additional requirements for deter-
mining the eligibility of a donor . . . on the day of donation”). 
       81. See generally Rehman et al., supra note 17. 
       82. 21 C.F.R. § 630.10(h) (citing to 21 C.F.R. § 630.40 (2016)). 
       83. 21 C.F.R. § 610.41 (2016); see 21 C.F.R. § 630.10(g)(i), (h). 
       84. 21 C.F.R. § 610.41; 21 C.F.R. § 630.10(h). See also FDA, REQUALIFICATION OF DONORS 
PREVIOUSLY DEFERRED FOR A HISTORY OF VIRAL HEPATITIS AFTER THE 11TH BIRTHDAY (Sept. 2017), 
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are characterized by the donor being prohibited from donating on the specific occa-
sion they are deemed ineligible but do not automatically preclude the donor from 
future donations if the reason for the prior deferral is no longer applicable.85 A tem-
porary deferral also covers a deferral that only prohibits donation for a fixed period 
of time.86 On the other hand, a permanent deferral prohibits the donor from any 
future blood/blood component donation absent some explicit exception provided 
for in the regulation.87 This more serious deferral is enforced after the post-donation 
testing yields evidence of infection from one of the relevant transfusion-transmitted 
infections described in § 630.3(h)(1), including Human Immunodeficiency Virus 
(“HIV”), strains of hepatitis, syphilis, West Nile virus, and malaria.88 Narrow ex-
ceptions to permanent deferral can be found if the donor tested reactive to a certain 
infections on only one occasion prior to the current donation.89 Regardless of allow-
ing an exception, every establishment involved in the collection and supply of do-
nated blood must maintain comprehensive records of all deferred donors upon de-
termination of a donor’s prior ineligibility.90 
As noted above, further regulation also provides for certain exceptions or re-
qualification of deferred donors.91 However, beyond defining which donors may 
potentially be excepted or re-qualified, 21 C.F.R. § 610.41(b) does not provide any 
further instruction for how organizations can assist indefinitely deferred donors to-
ward future eligibility to donate.92 The language states that “a deferred donor may 
be subsequently found to be eligible as a donor of blood or blood components by a 
requalification method or process found acceptable for such purposes by the FDA. 
Such a donor is considered no longer deferred.”93 Although the FDA has, on occa-
sion, offered additional guidance regarding re-qualification of donors, it is often 
narrowly targeted, circularly reasoned, and left to the discretion of establishments.94 
At most, these regulations put blood collection organizations in a position to enter 
a maze of deferred donor policy without a voice or a light to guide them—and most 
organizations opt to leave the deferred donor issues alone rather than blindly navi-
gate the maze. 
                                                          
https://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInfor-
mation/Guidances/Blood/UCM574574.pdf [hereinafter REQUALIFICATION OF DONORS PREVIOUSLY 
DEFERRED] (noting that permanent deferrals are also identified as “indefinite” deferrals). 
       85. 21 C.F.R. § 630.35(a) (2016). 
       86. Id. 
       87. Id. § 610.41(a). 
       88. 21 C.F.R. § 610.40(a)(1)-(3) (2016); see 21 C.F.R. § 630.3(h)(1)(i)–(x) (2016) (enumerating all 
other relevant transfusion-transmitted infections and strains: HIV types I and II, Hepatitis B virus, Hep-
atitis C virus, Human T-lymphotropic virus types I and II, syphilis, West Nile virus, Chagas disease, 
Creutzfeldt-Jakob disease, Variant Creutzfeldt-Jacob disease, and malaria). 
       89. 21 C.F.R. § 610.41(a)(1) (stating “a donor who tests reactive for anti-HBc or anti-HTLV types 
I and II” qualify for this exception. An additional exception exists under § 610.41(a)(3)-(4) for reactive 
donors who only donate plasma for pharmaceutical uses rather than for direct transfusion.). 
       90. 21 C.F.R. § 606.160(e) (2016). 
       91. REQUALIFICATION OF DONORS PREVIOUSLY DEFERRED, supra note 84, at 3. 
       92. 21 C.F.R. § 610.41(b). 
       93. Id. 
       94. See REQUALIFICATION OF DONORS PREVIOUSLY DEFERRED, supra note 84; see also FDA, 
RECOMMENDATIONS FOR REQUALIFICATION OF BLOOD DONORS DEFERRED BECAUSE OF REACTIVE 
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Since the federal government’s institution of the National Blood Policy in the 
1970s, each component of the policies, regulations, and statutes discussed above, 
as well as their drafters and authorities, have strived to maintain a blood supply that 
is adequate, high quality, accessible to its servicers, and efficient.95 Unfortunately, 
the good faith means used to pursue a strong blood supply—policies and statutes 
authorizing regulations that explicitly limit use of viable synthetic blood, implicitly 
limit transfusion of safe “paid donor” blood, and silently limit access to improperly 
deferred donors—may not justify the end. The success of that pursuit must be scru-
tinized in light of the ongoing blood supply shortage that has amounted into an un-
deniable threat to one of our most “critical national resources.”96 
III. THE CURRENT STATE OF BLOOD COLLECTION AND SUPPLY 
“The tragedy of life is often not in our failure, but rather in our complacency; 
not in our doing too much, but rather in our doing too little. . . .”97 As the blood 
supply becomes increasingly unstable, the real tragedy is the system’s complacency 
regarding the status quo. Dr. Arthur Caplan, the chairman of a 1999 Department of 
Health and Human Services committee to examine the country’s blood supply, 
stated, “Complacency is completely inappropriate with respect to the blood sup-
ply.”98 In the 1990s, the executive director of America’s Blood Centers  gave cre-
dence to the analysts who believed that if trends did not change, the blood supply 
would soon fail to keep up with the demand for blood.99 In 2019, it is clear that this 
prediction came true, and it continues to remain an issue inadequately addressed by 
those in a position to create change. 
A similarly prescient statement, made by industry leaders attempting to curtail 
a potential shortage in the 1990s, conceded how “repeated appeals for blood . . . 
could deafen potential donors to the point where, one day, they simply might not 
respond.”100 This prediction has also come to fruition in 2019 as blood collection 
establishments seem to inundate potential donors with marketing strategies and ex-
press pleas, urging “donors to give now”101 to build a sufficient supply and save 
                                                          
       95. Derek J. Jones, Ethical & Legal Issues in the Supply of Blood Products, BAYER ADVISORY 
COUNCIL ON BIOETHICS 34 (Dec. 1999), https://www.mcgill.ca/healthlaw/files/healthlaw/Jones_DJ_ Is-
sues_BloodSupply_1999.pdf. 
       96. Menitove, supra note 5. 
       97. Benjamin E. Mays, Complacency Quotes, BRAINY QUOTE, https://www.brainyquote.com/top-
ics/complacency (last visited Mar. 25, 2019). 
       98. Eric Nagourney, Blood Shortage: Answers Scarce, Too, N.Y. TIMES (Oct. 5, 1999), 
https://www.nytimes.com/1999/10/05/health/blood-shortage-answers-scarce-too.html. 
       99. Id. 
       100. Id. (identifying the head of the FDA’s blood-supply operation and the chief medical officer of 
the Red Cross at the time as industry leaders). 
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patients in need.102 Despite such a heavy reliance on marketing and emotional ap-
peals to encourage donors to give blood,103 more and more blood collection organ-
izations report that far too few potential donors respond to the call and donate.104 
Consequently, less than 10% of people eligible to give blood actually do so.105 
Focusing on this trend, ineffective approaches to marketing that are currently 
relied on may be seen as one of the reasons voluntary blood donation is not produc-
ing a sufficient blood supply. “Blood donation is a voluntary act and different or-
ganizations have to run rigorous campaigns to motivate the blood donors to make 
them realize how their contribution can save precious human lives.”106 Blood col-
lection organizations admittedly understand the importance of these campaigns but 
are shockingly reluctant to adapt to the social media platforms that would help com-
municate their message most successfully.107 Social media, more so than traditional 
platforms, can quickly and effectively distribute information to target audiences 
during critical situations.108 Considering how young people will necessarily be the 
future pool of potential donors, targeting them through various forms of social me-
dia and interactive outreach must become part of an organization’s best marketing 
practice.109 Relevant studies from Europe, Australia, and Arab regions concluded 
that targeting young people with mobile apps and social media will specifically in-
crease the  amount of new, young donors, as well as increase their sustained loy-
alty.110 
Complacency with the blood supply shortage in the United States is also per-
petuated by continued reliance on altruism and volunteerism alone, which is cur-
rently proven to be insufficient to supply the amount of blood demanded.111 There 
is a lack of personal connection in the current system because most blood donors 
do not know who will receive their blood.112 Generally, blood from paid donors is                                                           
       102. Red Cross: Blood Donors Needed, TIMES NW. IND. (Oct. 21, 2018), https://www.nwitimes.c 
om/news/local/lake/red-cross-blood-donors-needed/article_7bba51e2-fbbb-52b5-b12c-
7a33b235b81f.html. 
       103. Ashwin Aravindakshan, Oliver Rubel & Oliver Rutz, Managing Blood Donations with Mar-
keting, 34 MARKETING SCI. 1 (Mar. 2015), https://www.researchgate.net/publication/270220057_Man-
aging_Blood_Donations_with_Marketing. 
       104. John R. Hackett Jr., A Plea to Young Americans: Donate Blood, U.S. NEWS (June 14, 2018, 
6:00 AM), https://health.usnews.com/health-care/for-better/articles/2018-06-14/a-plea-to-young-ameri-
cans-donate-blood. 
       105. Facts & Figures, AM.’S BLOOD CTRS., https://www.americasblood.org/about-blood/facts-fig-
ures.aspx (last visited Mar. 24, 2019). 
       106. Rabeeh Ayaz Abbasi et al., Saving Lives Using Social Media: Analysis of the Role of Twitter 
for Personal Blood Donation Requests and Dissemination, 35 TELEMATICS & INFORMATICS 892, 895 
(2017). 
       107. Id. 
       108. Id. 
       109. Marcus Foth et al., Social and Mobile Interaction Design to Increase the Loyalty Rates of 
Young Donors, PROC. 6TH INT’L CONF. ON COMMUNITIES & TECH. 64 (2013), 
https://eprints.qut.edu.au/59928/14/59928a.pdf. 
       110. Id.; see also Covadonga Aldamiz-echevarria & Maria Soledad Aguirre-Garcia, A Behavior 
Model for Blood Donors and Marketing Strategies to Attract Them, 22 REV. LAT. AM. ENFERMAGEM 
467 (2014), https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4292625/; Abbasi et al., supra note 106, at 
910; John Healy & Maurice Murphy, Social Marketing: The Lifeblood of Blood Donation?, in THE 
CUSTOMER IS NOT ALWAYS RIGHT? MARKETING ORIENTATIONS IN A DYNAMIC BUSINESS WORLD 811 
(Colin L. Campbell ed., 2017), https://link.springer.com/chapter/10.1007/978-3-319-50008-9_222. 
       111. Kathleen Chell et al., A Systematic Review of Incentives in Blood Donation, 58 J. AABB: 
TRANSFUSION 242, 242 (Jan. 2018), https://onlinelibrary.wiley.com/doi/10.1111/trf.14387. 
       112. Donating Blood, AM. CANCER SOC’Y, https://www.cancer.org/treatment/treatments-and-side-
effects/treatment-types/blood-transfusion-and-donation/donating-blood.html (last updated Apr. 7, 2017) 
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not used in the United States for transfusions.113 Although the FDA does not entirely 
prohibit the paid blood donation,114 direct payment and any other type of economic 
incentive are widely discouraged by the FDA’s published guidance, which impacts 
hospitals’ policies regarding paid donor blood.115 Aside from economist Mario 
Macis’s reasoning above that a hospital’s anti-paid donor policy is driven by ethical 
perceptions,116 a pragmatic, common sense perspective may simply reason that hos-
pital boards are hesitant to openly deviate from the FDA’s stance. Regardless of 
why the FDA and hospitals continue to advance a strong preference for volunteer 
blood, the reality is that they do—creating a constriction on the blood supply that is 
not workable as the nation’s shortage reaches more critical levels. 
A study conducted in Germany, one of the first countries to allow direct cash 
payments for blood donation, found that blood donations decrease when payment 
to donors is stopped.117 Importantly, donation levels did not recuperate after pay-
ment was ceased.118 The study concluded that direct incentivization is a powerful 
tool to prevent and mitigate blood shortages.119 At a minimum, the FDA and Amer-
ican hospitals should concede the potential for economic incentives to positively 
influence blood donation. However, mere recognition of a potential solution with-
out subsequent action is the exact type of complacency that the current blood short-
age is rooted in. 
Another basis for the suffering blood supply is current FDA regulation—first, 
the prohibition against synthetic blood products and second, the disgraceful conduct 
regarding some types of deferred donors. Currently, no oxygen-carrying blood sub-
stitutes are approved for use by the FDA.120 The resistance against funding and us-
ing a substitute for human blood is due to one “poorly designed clinical trial” in 
2008.121 Since then, the FDA has not changed its official position even though 
“There has been a need for blood replacements for as long as patients have been 
bleeding to death because of a serious injury”; the FDA does recognize the potential 
for its use as an alternative to human blood, though.122 Reconsidering this stance 
                                                          
[hereinafter Donating Blood]. See generally Directed Blood Donations, MAYO CLINIC, https://web.ar-
chive.org/web/20080828202500/http://www.mayoclinic.org/donate-blood-rst/directed.html (last visited 
Mar. 25, 2019) (defining that a “directed blood donation,” which is not the norm in the U.S., occurs 
when “the patient identifies family members or friends who will donate blood for the patient’s surgery”). 
       113. Donating Blood, supra note 112. 
       114. VOX SANGUINIS, supra note 69, at 69. 
       115. See id. at 70; Preston, supra note 71; FDA, CPG SEC. 230.150 BLOOD DONOR CLASSIFICATION 
STATEMENT, PAID OR VOLUNTEER DONOR (Nov. 11, 2011), https://www.fda.gov/ucm/groups/fdagov-
public/@fdagov-afda-ice/documents/webcontent/ucm122798.pdf. 
       116. Preston, supra note 71. 
       117. David M. Becker et al., The Impact of Direct Cash Payments on the Whole Blood Supply, SSRN 




       118. Id. 
       119. Id. at 27. 
       120. A.I. Alayash, Evaluating the Safety and Efficacy of Hemoglobin-Based Blood Substitutes, FDA, 
https://www.fda.gov/biologicsbloodvaccines/scienceresearch/biologicsresearchareas/ucm127061.htm 
(last visited Mar. 25, 2019). 
       121. Notman, supra note 18. 
       122. Suman Sarkar, Artificial Blood, 12 INDIAN J. CRITICAL CARE MED. 140 (July 2008), https:// 
www.ncbi.nlm.nih.gov/pmc/articles/PMC2738310/; Andrew Joseph, The Quest for one of Science’s 
Holy Grails: Artificial Blood, STAT (Feb. 27, 2017), https://www.statnews.com/2017/02/27/artificial-
blood-substitute/. 
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has the potential of alleviating the threats facing the blood bank system as well as 
surging the economy with an estimated $7.6 billion in estimated sales.123 
The approach toward blood donor deferral regulations in the United States is 
also complacent and serves as another avoidable cause of the blood shortage. Cas-
ually stated, “[w]hen a person is turned away from a blood donation, he or she” 
does not usually return.124 For donors who are deferred temporarily, a lack of edu-
cational material reminding them to come back and donate again could represent 
why the United States is consistently unable to put the blood supply on more stable 
footing.125 Donors who are deferred indefinitely, whether correctly or not, are more 
turned off from pursuing re-qualification for future donations.126 Ignoring the ac-
tual, negative impacts of improperly applied donor deferral regulation is not an op-
tion for the FDA while the consequences of the blood shortage loom large. 
Doctors with a policy-minded focus agree that “balance is key for any change 
in blood-donation policy, keeping in mind the dual goals of increasing the pool of 
eligible donors in the U.S. and maintaining the safety of anyone who receives do-
nated blood.”127 Fortunately, solutions that emphasize achievement of these dual 
goals exist for each of the shortcomings present in the status quo. A reconsideration 
of the system is more vital now than ever to secure the blood supply—and therefore 
the nation’s public health—now and in the future.128 
IV. RECONSIDERING THE CURRENT SYSTEM TO SOLVE FOR THE 
BLOOD SHORTAGE  
Although express efforts in the 1970s helped render it functional and effective 
for many decades, the time has come for focused and intentional changes in the 
blood supply system; it is time to modernize and realize new, actionable goals nec-
essary to strengthen one of our country’s most important yet vulnerable resources. 
It cannot be overstated that regaining and maintaining a safe, adequate blood supply 
(1) is fundamental to the nation’s public health, (2) is a “priority for the medical 
community,”129 and (3) should be a priority to the executive agencies capable of 
creating the change that is needed. Notably, there are various changes that can be 
made to solve for the inadequate supply without sacrificing the safety of donors and 
patients. 
                                                          
       123. Sarkar, supra note 122. 
       124. Shalmali Pal, Blood Donation: Separating Myth from Fact, AM. SOC’Y HEAMATOLOGY 
CLINICAL NEWS (Jan. 1, 2018), https://www.ashclinicalnews.org/features/blood-donation-separating-
myth-fact/. 
       125. Id. 
       126. Id. 
       127. Id. 
       128. Significant Shortages Impact, supra note 12. 
       129. Id. 
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A.  Modernizing Blood Collection Organizations’ Approach 
to Marketing 
Focusing on younger generations who are the future of the blood supply means 
that marketing tactics must also shift to the platforms utilized by these genera-
tions.130 Studies have consistently shown that the use of applications like Twitter or 
Snapchat have the potential to disseminate information more rapidly and consist-
ently to its audiences.131 There are multiple factors that can increase the impact of 
social media marketing, and blood collection organizations have, at best, a weak 
argument for not taking advantage of them. Mentioned above, these organizations 
only state a reluctance to adopt modern marketing techniques available through so-
cial media.132 Despite feeling reluctant, there are many ways for blood collection 
organizations in the United States to slowly find their footing in the modern mar-
keting realm, especially because countries around the world have been doing so for 
years. 
One example is found in Sweden. A Swedish blood service noticed consistently 
declining blood donation rates in developing countries all around the world and they 
decided to try utilizing automatic text messages to increase blood donations.133 
Something as simple as an automated message, which efficiently connects all the 
essential people within the blood supply industry, was found to boost donations 
greatly.134 Additionally, campaigns like this were widely popular on social media 
and effectively generated awareness with the young audience about donating 
blood.135 Organizations in the United States could realistically utilize these same 
tactics and reap the benefit of increased donation without impacting safety. 
B.   Normalizing Economic Incentives to Attract and Retain 
Donors 
Empirical data from studies conducted in other countries shows the effective-
ness of direct payment for blood donation. In the United States, payment is already 
authorized for plasma donations, and it is not an unreasonable leap to allow payment 
for red blood cell donation.136 Although the FDA has put great effort into publishing 
their concern over payment for donated blood (e.g., paying donors may incentivize 
infected donors to hide their medical history in order to receive the donation pay-
ment),137 the reality of the blood supply shortage outweighs their arguments. 
                                                          
       130. Liis Hainla, 21 Social Media Marketing Statistics You Need to Know in 2018, DREAM GROW, 
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Considering that the FDA has such extensive, secure testing requirements for 
the blood that is donated, the minor flux in tainted blood can and would be screened 
out, while the increase of transfusable blood will be passed along to waiting pa-
tients.138 Additionally, in Germany, a fairly similar developed country to the United 
States, direct payment has been shown to allow the blood supply to be adequately 
maintained without compromising the safety of the blood transfused.139 Regardless 
of the opportunity to aid the blood supply, the FDA officially commented that paid 
donation risks the safety of blood.140 Therefore, the FDA refuses to endorse paid 
donations because it intends for all screening of donated blood to be redundant, 
“like layers of an onion.”141 
A consistent compensation scheme will also allow for the existence of the com-
pensation to become more widely known, and, over time, blood will be supplied 
more willingly. Although volunteerism and altruistic values supported the blood 
supply for decades, the waning level of current donations proves that is simply not 
the case anymore.142 This is not to say that blood donation should cease to be rec-
ognized as a good deed. Rather, donors can be more effectively drawn in by com-
bining people’s tendency to take altruistic action with a direct, external incentive 
that increases the likelihood of getting donors in the door. 
Potential economic incentives, such as cash payment, tax deductions, or cou-
pons,143 would require changes in U.S. statutory authority and in the tone of the 
FDA’s guidance. Upheld by the Supreme Court in Lary v. U.S., the Internal Reve-
nue Service (“IRS”) does not allow a donor to “claim a charitable deduction” based 
on either “performance of a service” or “contribution of property. . . .”144 Interest-
ingly, if an individual receives payment for a blood donation, they must report that 
income to the IRS.145 
To allow for maximum attraction and retention of donors, the government and 
blood collection organizations should mandate direct payments, even if subject to 
income tax; or the system could maintain its altruistic nature but provide donors a 
tax incentive. Either way, the safety of the blood supply is minimally compromised, 
and the blood supply could be bolstered. 
C.  Necessary Changes to Current FDA Regulations of 
Blood Collection and Supply 
i. Clarification of Deferred Donor Requalification 
The FDA needs to either provide internal clarification and guidance for how 
blood collection organizations can assist deferred donors in re-qualifying, or it must 
relax some of the standards that are based on false-positive reactivity. Once a donor 
is turned away—whether the determination of their deferral was erroneous or not—
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it is unlikely they will return to donate again.146 This is a significant loss in the 
amount of willingly donated blood that the status quo cannot bear to part with unless 
the deferral is better explained to the people impacted by it. 
In 2014, the author of this article was indefinitely deferred by one of the large 
blood collection organizations following a false-positive reactivity to Hepatitis-B. 
Prior to the deferral, the author donated blood as often as allowed and never had 
any issues—she was, and planned to remain, a loyal, repeat donor. Since the defer-
ral, though, the author’s personal experience seeking requalification has proved 
confusing and futile. Although the author takes issue with the fact that inaccurate 
reactivity testing led to her deferral, it is more concerning that blood organizations 
were seemingly comfortable losing a reliable donor at a time when knowledge of 
the shortage was first emerging. 
If the FDA provides greater, clearer guidance to blood organizations, the author 
may not still be deferred. If the FDA required blood organizations to follow up on 
improperly deferred donors, the author would no longer be deferred and, accord-
ingly, would be donating regularly. While investigating this issue, the author real-
ized that her situation was not a rarity. To the contrary, a handful of the author’s 
personal acquaintances have dealt with the same improper deferral and a similar 
lack of follow-up by the organizations. 
ii. Regular Use of Synthetic Blood Alternatives 
Synthetic blood has been tested tirelessly, and, although it would be a dramatic 
shift in the blood supply’s historic reliance on human blood,147 such utilization may 
have positive impacts on the threatened blood supply. The FDA has recognized this 
alternative’s potential to be lifesaving in situations where blood transfusions are 
necessary, but where human-donated “blood is not available or can’t be used.”148 
Debates over the efficacy of synthetic blood is holding the FDA back from seriously 
considering its approval for transfusion,149 despite scientific proof that synthetic 
blood alternatives at least work as a short-term replacement.150 
Not only will a product like synthetic blood be practically available in every 
instance it is needed, it could also surge the economy greatly.151 One existing alter-
native to human blood is a hemoglobin-based oxygen carrier (“HBOC”). The prag-
maticism of HBOCs is that they are universally compatible, meaning the patient’s 
blood type will not be an issue when performing transfusions.152 Further, a unit of 
HBOC is “stable at room temperature for at least three years,” undoubtedly creating 
a much more secure blood supply than refrigerated human-donated red cells that 
are only viable for a maximum of 42 days.153 
The benefits that this product would practically provide, plus the scientific as-
sertions promoting the product’s reliability and the economic assertions predicting 
a boost in the nation’s economy, as mentioned earlier, make it a solution that cannot 
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be ignored any longer.154 At the very least, limited approval of synthetic blood could 
serve to alleviate the tension of a low blood supply while the FDA and blood col-
lection organizations work to implement the other changes necessary to save the 
industry and the lives that depend on it. It is the author’s assertion that mandating 
funds for research of synthetic blood alternatives is equally as necessary to expedite 
future approval of their wide-spread use in transfusions. 
V. CONCLUSION 
The shortage of a critical national resource has never been taken lightly in the 
United States, and the blood supply should be no different. After a decade of in-
creasing vulnerability in the supply of a life-giving resource, the complacency of 
blood supply actors and the inflexibility of its controls must be reevaluated. Blood 
collection organizations can abandon improper, unwarranted reluctance toward 
marketing strategies that will successfully increase donations; the FDA’s guidance 
and hospitals’ policies can abandon archaic theories encouraging pure volunteerism 
while discouraging economic incentives shown to increase donations; the FDA can 
abandon unnecessarily restrictive regulations against certain deferred donors and 
synthetic blood products that would otherwise increase donations. Therefore, our 
blood supply can realistically regain its vitality. Most glaring is that these are spe-
cific solutions that could address the significant problems of the blood supply while 
maintaining its safety. Whether one or all of these solutions are adopted, it is time 
to return the favor of a life-giving transfusion to the blood supply system that has 
been saving our lives for decades. 
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